#1 Clinical Trials Search in Europe

Oregovomab

Oregovomab is an experimental drug being studied in clinical trials for the treatment of ovarian cancer. This article explores the use of Oregovomab in various clinical trials, its potential benefits, and its role in immunotherapy for ovarian cancer patients. We’ll discuss how Oregovomab works, its combination with other treatments, and the ongoing research to determine its effectiveness in improving patient outcomes.

Table of Contents

What is Oregovomab?

Oregovomab, also known by its brand name OvaRex[1], is an experimental drug being studied for the treatment of ovarian cancer. It belongs to a class of medications called immunotherapies, which work by stimulating the body’s own immune system to fight cancer cells[2].

How Does Oregovomab Work?

Oregovomab is designed to target a specific protein called CA 125, which is often found in high levels in patients with ovarian cancer. By attaching to CA 125, oregovomab helps the immune system recognize and attack cancer cells more effectively. This process is known as immunotherapy, and it aims to create an immune response that enables the body to fight the disease[2][1].

What Conditions Does Oregovomab Treat?

Oregovomab is primarily being studied for the treatment of:

  • Epithelial ovarian cancer: This is the most common type of ovarian cancer, which starts in the cells that cover the outer surface of the ovary[1].
  • Fallopian tube cancer: Cancer that begins in the fallopian tubes, which connect the ovaries to the uterus[2].
  • Peritoneal cancer: Cancer that develops in the peritoneum, the thin layer of tissue that lines the abdomen[2].

Clinical Trials and Research

Several clinical trials are currently underway to evaluate the effectiveness and safety of oregovomab in treating ovarian cancer. These trials are investigating various aspects of the drug, including:

  • Post-chemotherapy consolidation: Some studies are looking at using oregovomab after initial chemotherapy to help maintain the treatment’s effects and prevent cancer recurrence[3].
  • Combination with front-line chemotherapy: Researchers are exploring the potential benefits of using oregovomab alongside standard chemotherapy treatments[2].
  • Combination with other immunotherapies: Studies are investigating the use of oregovomab in combination with other immunotherapy drugs, such as nivolumab, to potentially enhance the immune response against cancer cells[1].
  • Different dosing regimens: Trials are comparing various dosing schedules to determine the most effective way to administer oregovomab[4].

How is Oregovomab Administered?

Oregovomab is typically administered through intravenous (IV) infusion, which means it is given directly into a vein. The dosage and frequency of administration can vary depending on the specific clinical trial or treatment plan. Some common dosing regimens being studied include:

  • 2 mg given every 4 weeks[1]
  • 2 mg given monthly for a certain number of doses, followed by less frequent administration[4]
  • Varying doses (0.5 mg, 1 mg, or 2 mg) given every 4 weeks, depending on the patient’s response and tolerability[1]

Combination Therapy with Oregovomab

Recent clinical trials are exploring the potential benefits of combining oregovomab with other cancer treatments to enhance its effectiveness. Some notable combinations include:

  • Oregovomab with chemotherapy: Studies are investigating the use of oregovomab alongside standard platinum-based chemotherapy drugs for ovarian cancer[5].
  • Oregovomab with nivolumab: This combination aims to boost the immune system’s ability to fight cancer cells. Nivolumab is another type of immunotherapy that works by blocking a protein called PD-1, which can help cancer cells hide from the immune system[1][5].

Potential Side Effects and Safety

As with any medication, oregovomab may cause side effects. Clinical trials are carefully monitoring patients for adverse events to ensure the safety of the treatment. Some of the aspects being evaluated include:

  • Incidence and severity of adverse events: Researchers are tracking any side effects that occur during treatment, ranging from mild to severe[1].
  • Long-term safety: Studies are following patients for extended periods (up to 3 years in some cases) to assess the long-term safety of oregovomab[1].
  • Quality of life: Some trials are evaluating how oregovomab treatment affects patients’ overall quality of life[3].

It’s important to note that oregovomab is still an experimental drug, and more research is needed to fully understand its safety profile and potential side effects. Patients considering participation in clinical trials should discuss the potential risks and benefits with their healthcare providers.

Aspect Details
Drug Name Oregovomab (also known as OvaRex® MAb-B43.13)
Type of Treatment Immunotherapy
Target Cancer Ovarian, Tubal, or Peritoneal Cancer
Administration Intravenous (IV)
Clinical Trial Phases Phase I, II, and III
Combination Therapies Chemotherapy, Nivolumab
Key Outcomes Measured Safety, Immune Response, Progression-Free Survival, Overall Survival
Dosing Schedules Varied (e.g., monthly, quarterly, or other intervals)
Patient Population Newly diagnosed and recurrent ovarian cancer patients

FAQ

  • What is Oregovomab? Oregovomab is an experimental drug being tested as an immunotherapy treatment for ovarian cancer. It is designed to help the body's immune system recognize and fight cancer cells.
  • How is Oregovomab administered? Oregovomab is typically administered intravenously (through an IV) in various dosing schedules, depending on the specific clinical trial. Some trials use it as a single agent, while others combine it with chemotherapy or other immunotherapy drugs.
  • What types of ovarian cancer is Oregovomab being studied for? Oregovomab is being studied for various types of ovarian cancer, including epithelial ovarian cancer, tubal cancer, and peritoneal cancer. It is being tested in both newly diagnosed patients and those with recurrent disease.
  • Are there any side effects associated with Oregovomab? As with any experimental treatment, there may be side effects associated with Oregovomab. Clinical trials are designed to monitor and assess the safety of the drug. Patients in these trials are closely monitored for any adverse events or reactions to the treatment.
  • How does Oregovomab work with other cancer treatments? Some clinical trials are exploring the use of Oregovomab in combination with other treatments, such as chemotherapy and other immunotherapy drugs like Nivolumab. The goal is to determine if these combinations can enhance the effectiveness of cancer treatment and improve patient outcomes.

Ongoing Clinical Trials on Oregovomab

  • Study Comparing Paclitaxel, Carboplatin, and Oregovomab with Paclitaxel, Carboplatin, and Placebo for Patients with Advanced Ovarian Cancer

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Hungary Italy Spain

Glossary

  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer cells.
  • Epithelial Ovarian Cancer (EOC): The most common type of ovarian cancer that starts in the cells covering the outer surface of the ovary.
  • CA 125: A protein found in higher amounts in ovarian cancer cells, often used as a tumor marker for ovarian cancer.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer getting worse.
  • Overall survival (OS): The length of time from the start of treatment until death from any cause.
  • Complete Response (CR): The disappearance of all signs of cancer in response to treatment.
  • Partial Response (PR): A decrease in the size of a tumor or in the extent of cancer in the body in response to treatment.
  • Stable Disease (SD): Cancer that is neither decreasing nor increasing in extent or severity.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or level of treatment.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.

References

  1. https://clinicaltrials.gov/study/NCT03100006
  2. https://clinicaltrials.gov/study/NCT00086632
  3. https://clinicaltrials.gov/study/NCT00050375
  4. https://clinicaltrials.gov/study/NCT00034372
  5. https://clinicaltrials.gov/study/NCT04620954